1 Registry for vascular cognitive impairment treatment with traditional Chinese

2 medicine (REVIEW-TCM): Rationale and design of a prospective, observational

- 3 study
- 4 Yao Xie, PhD¹, Le Xie, PhD¹, Junlin Jiang, PhD¹, Ting Yao, MD¹, Guo Mao, PhD²,
- 5 Rui Fang, PhD³, Fuliang Kang, MD⁴, Shiliang Wang, MD¹, Anchao Lin, MD¹, Ying
- 6 Gao, PhD⁵, Jinwen Ge, PhD¹, Dahua Wu, PhD¹.

7 Author affiliations

- 8 1. Department of Neurology, Hunan Hospital of Integrated Traditional Chinese and
- 9 Western Medicine, Changsha, China
- 10 2. Office of Academic Research, Hunan Hospital of Integrated Traditional Chinese and
- 11 Western Medicine, Changsha, China
- 12 3. College of Integrated Chinese and Western Medicine, Hunan University of Chinese
- 13 Medicine, Changsha, China
- 14 4. Department of Imaging, Hunan Hospital of Integrated Traditional Chinese and
- 15 Western Medicine, Changsha, China
- 16 5. Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing, China

17 Corresponding author:

- 18 Dahua Wu. Postal address: Department of Neurology, Hunan Hospital of Integrated
- 19 Traditional Chinese and Western Medicine, Changsha, China, 410006. Email:
- 20 wdh838692@sina.com
- 21 Jinwen Ge. Postal address: Department of Neurology, Hunan Hospital of Integrated
- 22 Traditional Chinese and Western Medicine, Changsha, China, 410006. Email:
- 23 001267@hnucm.edu.cn
- 24
- 25

26 Abstract

Background: Vascular cognitive impairment (VCI) is one of the most common diseases among the elderly. However, few effective drugs have been approved for VCI. Traditional Chinese medicine (TCM) has been used in dementia for thousands of years. Currently, there is limited high-quality evidence for the efficacy of TCM, and the specific characteristics of its effects and the appropriate patient populations for TCM therapies remain unclear. Herein, we aim to explore the effectiveness and safety of TCM by conducting a longitudinal, patient-centered study.

Methods: REgistry for Vascular cognitive Impairment trEatment With Traditional
Chinese Medicine (REVIEW-TCM) is a prospective, observational disease registry
study. 1000 VCI patients at the Hunan Hospital of Integrated Traditional Chinese and
Western Medicine will be recruited based on the following criteria: aged 18 years or
older, Montreal Cognitive Assessment (MoCA) score < 26, and Hachinski Ischemic
Score (HIS)≥7. There is no strict limit on the intervention, and different TCM formulas

40 will be focused. Cognition, activity of daily living, quality of life, mental, psychology, 41 *ZHENG* of TCM, and burden of caregiver will be evaluated at admission, and 6, 12, 18, 42 and 24 months. Meanwhile, biological tests and neuroimaging examination will be 43 applied to further explore the mechanism of TCM. Especially, a mixed-methods 44 embedded design will be applied by adopting quantitative and qualitative studies to 45 explore patients-reported outcomes of TCM. Finally, propensity score matching will be 46 adopted to analyze the effectiveness of TCM.

47 Discussion: To the best of our knowledge, the REVIEW-TCM study is the first 48 comprehensive, prospective, mixed-methods, registry-based study to evaluate TCM 49 treatment in VCI, which will analyze the effectiveness and safety of TCM in the real 50 world and explore population characteristics and subtypes of VCI suitable for TCM.

51 Study registration: This study was registered on <u>www.chictr.org.cn</u>
52 (ChiCTR2200064756).

54 Introduction

55 Vascular cognitive impairment (VCI) refers to the entire spectrum of vascular brain 56 pathologies that contribute to any degree of cognitive impairment [1]. VCI can be 57 classified as mild or major, with the latter also being known as vascular dementia (VaD). 58 Over the past few years, vascular mild cognitive impairment has become increasingly 59 common, with a reported prevalence of around 42% in people over 65 years old [2]. In 60 China, there are currently an estimated 2.49 million patients with vascular dementia [3]. 61 It is well-established that patients with VCI can experience a range of cognitive and 62 quality-of-life impairments. The commonly impaired cognitive domains in VCI 63 patients involve executive function, attention, and processing speed [4], which can 64 hinder processes for initiation, planning, decision-making, hypothesis generation, cognitive flexibility, and judgment. In addition, other clinical features such as gait 65 disturbance, urinary incontinence, and emotional disorders can make work and daily 66 life more arduous [5]. 67

Due to the gradual decline in their cognitive abilities, individuals with VCI may become 68 69 increasingly dependent on others for their activities of daily living, which can lead to a 70 decline in their overall well-being. Experiencing anxiety and depression is very 71 common in people with cognitive impairment [6], and emotional disorders can also 72 affect the caregiver. Indeed, the caregiver burden will remarkably increase under caring 73 for major cognitive impairment [7]. Accordingly, during the treatment of VCI, 74 behavioral and psychological symptoms should be addressed, providing support for patients and caregivers and maximizing independence [8]. 75

76 The current medical approach for VCI treatment often exhibits limited efficacy, as 77 cholinesterase inhibitors and memantine provide minimal benefits [9]. Traditional 78 Chinese medicine (TCM) has been used in dementia for thousands of years. There is an 79 increasing consensus that Chinese medicine is beneficial for VCI [10-13]. Many studies 80 have shown positive effects in improving cognitive impairment, psychological 81 symptoms and quality of life [14]. However, there is limited high-quality evidence for 82 TCM, and it remains uncertain which patient populations and therapeutic approaches 83 are most appropriate and effective. Meanwhile, the course of treatment and effective 84 combination therapies warrant further investigation [15].

Indeed, a prospective observational study with regular and long-term follow-ups can
 address the above questions. Registry for vascular cognitive impairment treatment with

traditional Chinese medicine (REVIEW-TCM) aims to investigate the characteristics and effectiveness of TCM for VCI in the Chinese population. The key factors affecting the clinical effectiveness and suitable population characteristics for TCM will be explored. In addition, the neuroimaging scan images and blood samples will be collected for further mechanism research. Finally, the perspective of patients and caregivers will be analyzed to explore patient-reported outcomes of TCM.

93 Methods and design

94 Study design

95 The REVIEW-TCM study (registered with www.chictr.org.cn, ChiCTR2200064756)
96 is a prospective observational disease registry that utilizes a mixed-methods approach,
97 incorporating both quantitative and qualitative study designs. Figure 1 and Figure 2
98 provide an overview of the study. The research protocol has been approved by Hunan
99 Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China,
100 on 20 July, 2022. (No. [2022] 48).

101 **Patient population**

102 Patients aged 18 years or older were consecutively recruited from Hunan Hospital of 103 Integrated Traditional Chinese and Western Medicine, from October 30, 2022 to 104 December 31, 2027. The special symposium of the International Society for Vascular 105 Behavioral and Cognitive Disorders (VASCOG) [16] will be adopted to diagnose VCI, 106 the Montreal Cognitive Assessment (MoCA) score should be lower than 26, and the 107 Hachinski Ischemic Score (HIS) should be greater than 6. The exclusion criteria are as 108 follows: (1) patients diagnosed with Alzheimer's disease, frontotemporal dementia, 109 Lewy body dementia, Parkinson's disease, multiple sclerosis, brain trauma and other 110 neurological diseases leading to cognitive impairment; (2) patients with altered levels 111 of consciousness, unstable vital signs or serious cardiopulmonary diseases; (3) patients 112 unable to complete the study due to psychological or emotional disorders, severe audio-113 visual disorders. All participants or proxies should give informed consent.

114 Specific treatment

There is no strict limitation placed on the intervention. We will focus on TCM treatment and pay attention to the detailed information, including herbs in prescriptions, formulation (Chinese patent medicine and TCM decoctions), duration (start and stop times), and therapy compliance. The rest of the treatment protocol are according to guidelines, including donepezil, galantamine, rivastigmine, memantine, butylphthalide,

120 citicoline, cognitive rehabilitation training, etc [4].

121 **Neuropsychological Assessments**

122 The cognitive scales selected are based on the recommendations from the vascular 123 impairment of cognition classification consensus study (VICCCS) [17]. MoCA will be 124 used to assess general cognitive function. Trail Making Test A (TMT-A) and Test B 125 (TMT-B) will be applied to measure patients' processing speed and executive function. 126 The verbal learning, recognition memory, and recall will be evaluated by Hopkins Verbal Learning Test (HVLT). Language proficiency will be assessed using Boston 127 128 Naming Test, 2nd Edition (BNT-2). Visuospatial abilities will be evaluated with the 129 Clock Drawing Test (CDT). 130 Neuropsychiatric symptoms will be assessed using Neuropsychiatric Inventory (NPI).

131 Anxiety and depression will be measured by Hospital Anxiety and Depression Scale

- 132 (HADS). Disability will be assessed with Instrumental Activities of Daily Living
- 133 (IADL). Health-related quality of life will be assessed by the European Quality of Life-
- 134 5 Dimensions-5 Levels (EQ-5D-5L). The evaluators have accomplished standardized
- 135 training and kept good internal consistency.

136 **Evaluation of TCM syndromes**

- 137 The scale for the differentiation of syndromes of vascular dementia (SDSVD) will be
- applied to diagnose ZHENG and evaluate TCM's efficacy, including seven ZHENG of 138
- 139 TCM. The maximum score of each ZHENG in SDSVD is 30. If one TCM ZHENG's
- 140 score is at least 7, the diagnosis is established. We will choose the change scores after
- 141 treatment to verify the clinical efficacy of TCM.

142 **Burden of caregiver**

143 It is widely acknowledged that the caregivers who take care of VCI patients are 144 significantly more stressed, which leads to a decline in the caregiver's well-being. The

- 145 caregiver-oriented outcome will be assessed using the Zarit Burden Interview (ZBI),
- 146 with a total score of 88, involving 22 items. The role burden and personal burden will
- be assessed in ZBI. 147

148 **Biological Sample Tests**

Blood samples will be collected from participants who give informed consent. However, 149

- 150 participants diagnosed with infections, hematological disease, malignant tumors, and
- 151 other neurological diseases will be excluded. The serum and plasma will be collected
- 152 from ten milliliters of blood within 30min centrifuged at 3,000 r/min for 20 min. Then,
- 153 400ul serum or plasma in each polypropylene tube will be stored at -80°C. The

154 neurofilament light chain (NFL), C-reactive protein (CRP), leukocyte count (LC), and

155 vascular endothelial growth factor (VEGF) will be examined at regular intervals during

156 the study. The blood samples will be acquired from fasting patients at each visit.

157 (Supplementary Figure S1)

158 Imaging Examination and Analysis

159 Magnetic resonance imaging (MRI) will be performed on consenting participants who

160 are right-handed and have a HADS score < 8 and a modified Rankin scale (mRS) score

161 ≤ 2 . All participants should have no contraindications for MRI and without other 162 neurological diseases or psychiatric disorders. MRI acquisitions will be carried on 3.0 163 T GE Signa Scanner. The standardized neuroimaging protocol includes three-164 dimensional T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), magnetic 165 resonance angiography (MRA), and diffusion tensor imaging (DTI) sequence. The 166 infarct or hemorrhage lesions, white matter hyperintensity (WMH), vascular stenosis, hippocampal atrophy, mean diffusivity (MD), and fractional anisotropy (FA) will be 167 168 recorded. The neuroimaging analysis will be conducted by two experienced radiologists 169 independently. (Supplementary Figure S2)

170 **Patient-reported outcomes**

171 To explore the potential therapeutic effects of TCM, we plan to interview participants (VCI patients and their caregivers) undergoing TCM treatment for at least 3 months. 172 173 The score of MoCA in VCI patients should be between 10-26, and cognitive 174 impairment is their main symptom. All participants will be assessed by a 30 min semi-175 structured questionnaire, including disturbing symptoms, emotional needs, experience 176 of TCM, etc. The grounded analysis will be used to collect items on treatment effects and generate conceptual graphs, which will serve as the basis for developing patient-177 178 centered outcomes. Finally, the Delphi survey and verification research will be 179 conducted to obtain patient-reported outcomes [18] (Supplementary Figure S3).

180 **Data collection and monitoring**

All data will be collected on an electronic data capture (EDC) system (http://www.1dao.net) with unique ID during the study period. The main data elements include demographics, diagnosis, cognition, examination, imaging, treatments, outcomes, safety information, and other information (Table 1). Informed consent requires scanning and uploading. The EDC system can remind researchers of the time to follow up and automatically check for completeness and logical error in the uploaded data.

Any data correction and an electronic audit trail with an electronic signature and data
will be recorded on the system. To ensure the security of participant data, the EDC
system has implemented a strict authentication process.

190 **Follow-up procedures**

Participants will be scheduled for face-face visit every three months over two years. Researchers will provide specialized health services to ensure study compliance and keep in touch with participants and their caregivers by phone monthly. The treatment information, physical examination, four examinations of TCM, outcomes evaluation, safety assessment, and major adverse cardiovascular events (MACE) will be collected at each visit (at admission and at 6, 12, 18, and 24 months). Blood sample collection and MRI examination will be performed annually.

198 Study outcomes

199 To clarify the characteristics of the clinical efficacy of TCM therapies, the outcome will 200 be evaluated from multiple dimensions, including cognition, the activity of daily living, 201 quality of life, mental, psychology, ZHENG of TCM, the burden of caregiver, and 202 adverse events. The primary outcomes are the change scores of MoCA from baseline 203 to 12 months and 24 months. The secondary outcomes are the variation of MoCA, 204 TMT-A, TMT-B, HVLT, BNT-2, CDT, NPI, HADS, IADL, EQ-5D-5L, SDSVD, ZBI 205 from baseline to 12 and 24 months. The secondary outcomes will also include the 206 incidence of adverse events and MACE during the study. The exploratory outcomes 207 will be the change in NFL, CRP, LC, VEGF, MD, and FA.

208 Quality control and management

209 Prior to study initiation, a committee will design standard operating procedures 210 regarding consecutive patient screening and recruitment, obtaining informed consent, 211 and data collection. Research personnel, statistical analysts, and data administrator 212 should formulate the data verification plan together. Data administrators will regularly 213 review the uploaded data according to the verification plan, such as missing data, 214 logical errors, etc. Any questions about the uploaded data will be directed to the 215 investigator for clarification. The data administrators will be required to produce a 216 monthly data audit report.

217 Study sample size

Currently, there is no valid sample size calculation method for registry studies.
Multivariate analysis will be performed for the study outcomes. Based on the literature
and expert opinions, the preliminary research variables will be no more than 40.

According to the rule of thumb [19-20], the principle of sample size estimation should

be 20 times that of variables. Assuming a 20% dropout rate after the study is completed,

a total sample size of 1000 participants will be needed.

224 Statistical analysis

SPSS version 26 (IBM Corp., Armonk, NY, USA) will be applied for statistical analysis.
The baseline characteristics of all participants will be described as follows: the mean,
median, standard median, or interquartile ranges will be used to summarize continuous
data, while counts or percentages for categorical data. Between-group comparisons will
be conducted using ANOVA or t-test, or non-parametric tests.
The propensity score matching will be adopted to analyze the effectiveness of TCM.

Baseline variables will be balanced and matched, such as age, sex, education, hypertension, diabetes, smoking, stroke, cognition, brain lesion, etc. The comparative analysis will be conducted after the baseline unevenness adjustment. Propensity score matching will be used for comparisons, such as different therapies (TCM vs. western medicine vs. combined treatment), formulations (Chinese patent medicine vs. decoctions vs. formula granule), etc.

Hierarchical models based on the cognitive impairment grading, brain lesion size, age
group, gender, TCM syndromes, classification of diseases, course of treatment will be
taken into account to explore important factors affecting the effectiveness of TCM for
VCI. Conditional logistic regression models will be adjusted by different variables to
identify predictors of long-term effectiveness presented by MoCA and other outcomes
at 12- and 24-month follow-ups.

While quality control can improve the integrity of research data, missing data is often unavoidable in observational studies. However, limiting missing data to less than 20% is important. By convention, nonresponse follow-up will be classified as missing not at random (MNAR) [21]. Therefore, multiple imputations will be used to handle missing data [22].

248 **Discussion**

249 Given the diagnostic and treatment challenges of dementia, an increasing number of

250 observational studies have been conducted around the world, including the English

Longitudinal Study of Aging (ELSA) [23], the German Aging Survey (DEAS) [24],

and China Registry Study on Cognitive Impairment in the Elderly (HOPE) [25], with

253 few studies on VCI. A registry study is an organized system that collects medical data

254 in an observational format to evaluate clinical outcomes for specific diseases, health 255 conditions, or exposed populations [26]. To our knowledge, only one TCM registry 256 study [27] has focused on VCI, which just pay attention to one Chinese patent drug for 257 vascular dementia. Generally speaking, these data lack comprehensive TCM 258 information and multi-dimensional outcome assessment. The REVIEW-TCM study 259 will explore the efficacy characteristics, suitable patient populations, and patient-260 centered outcomes of TCM therapies. It is worth noting that specific studies with 261 hypotheses, such as comparative effectiveness research, pragmatic randomized clinical 262 trials, or nested case-control studies, can be included in this registry study. This 263 approach can lead to the generation of secondary hypotheses, which can be further 264 tested in clinical trials [28].

265 TCM treatment is mainly based on syndrome differentiation. ZHENG of TCM can 266 categorize different characteristics of VCI patients. According to ZHENG, different Chinese patent medicine and TCM decoctions can be prescribed by doctors. For 267 268 example, Qi Fu Yin can tonify gi and replenish blood to boost gi and blood circulation, 269 which includes bioactive compounds or phytochemicals to produce antioxidant, anti-270 inflammatory, and anti-thrombotic effects [29]. Therefore, Chinese herbs based on 271 different ZHENG can influence different pathological mechanisms and VCI 272 populations. Moreover, there is high-quality evidence supporting the use of Sailuotong 273 (SLT) for tonifying qi and activating blood [11,13]. SLT is reportedly effective against 274 VCI populations with mild to moderate severity dementia and evidence of ischemic 275 lesions, improving functioning in multiple domains, such as memory, orientation, 276 language and executive function [13]. Additionally, we sought to determine the specific 277 characteristics of TCM treatments that are most effective in treating VCI, as well as the 278 patient populations that are most likely to benefit from them.

279 Holism is a key principle of TCM which involves pursuing unity and integrity of 280 function in humans and keeping harmony with the social environment [30]. Besides 281 cognitive impairment, gait disturbance, urinary incontinence, emotional disorder, low 282 quality of life, and social role can impact VCI patients and caregivers. The REVIEW-283 TCM study will pay attention to cognitive functions, the changes in ADL, global 284 clinical improvement, quality of life, neuropsychiatric symptoms, and the burden of the 285 caregiver. However, some VCI patient-centered outcomes may not be found for TCM 286 treatment. Patient-reported outcomes will be explored in mixed methods research, 287 which integrates qualitative and quantitative methods for scientific inquiry and

evaluation to supplement outcomes [31]. Mixed methods research has been widely used
in real-world studies to comprehensively answer research questions, providing
abundant data for the individualized therapeutic evaluation of TCM in different aspects,
which may reflect holism and humanities characteristics of TCM at the individual level.

292 [32-33]

293 An increasing body of evidence suggests that white matter (WM) plays an important role in cognitive decline and dementia [34]. DTI is a kind of MRI technology to detect 294 295 microscopic structural changes in WM and evaluate the structural integrity of WM 296 fibers. It has become a potential candidate imaging marker to evaluate cognitive 297 impairment [35]. Accordingly, we will pay more attention to DTI in neuroimaging 298 examination to explore the effects of TCM on our brain structure. NFL is an 299 intermediate filament protein that is a component of the cytoskeleton of neurons and is 300 abundantly expressed in axons [36]. It is also a possible prognostic biomarker for VCI 301 and may serve as a pharmacodynamic response biomarker for therapeutic target 302 engagement [37]. Hypertension, diabetes, or other vascular risk factors can lead to 303 cerebrovascular injury. In contrast, angiogenesis and systemic inflammation 304 biomarkers, like VFGF, LC or CRP, may play a pathogenic role in driving cognitive 305 decline [38-39]. These biomarkers will improve our understanding of the 306 pharmacological mechanisms of TCM and represent potential therapeutic response 307 indicators.

308 It has long been established that TCM treatment can boost memory and cognitive 309 functions and manage behavioral and psychological symptoms associated with VCI. 310 We conducted a longitudinal, patient-centered study to comprehensively collect 311 epidemiological and clinical data for TCM research. To the best of our knowledge, the 312 REVIEW-TCM study is the first comprehensive, prospective, mixed-methods, registry-313 based study to evaluate TCM treatment in VCI, which will analyze differences among 314 different TCM therapies and the effectiveness and safety of TCM in the real world and 315 explore population characteristics and subtypes of VCI suitable for TCM.

- 316 Acknowledgments
- 317 We gratefully acknowledge the contributions of the researchers and all participants in this study.
- 318 We also thank Professor Ying Gao, Jinwen Ge, and DahuaWu for providing support on EDC
- 319 in REVIEW-TCM.
- 320 Authors' contributions

- 321 The idea of this research was proposed by YX. This protocol drafting was undertaken by YX,
- 322 LX, RF. DHW and JWG revised the manuscript for intellectual content. YG will provide
- 323 EDC system. Data collection and security will be performed by YX, JLJ, GM, TY, FLK,
- 324 SLW, ACL. All authors approved the final version of the manuscript.
- 325 Funding
- 326 This research was supported by General project of Health Commission of Hunan Province
- 327 (No.202218014505), General project of Hunan Administration of Traditional Chinese
- 328 Medicine (No.D2022060), Hunan Province Clinical Medical Technology Innovation
- 329 Guidance Project (No.2021SK51001), Natural Science Foundation of Hunan Province
- 330 (No.2022JJ40241), Foundation of China Center for Evidence Based Traditional Chinese
- 331 Medicine (No.2019XZZX-NB004), The National Key Research and Development Project
- 332 (No.2018YFC1704904).
- 333 Availability of data and materials
- 334 Not applicable
- 335 Declarations
- 336 Ethics approval and consent to participate

337 This study protocol involving human participants has been reviewed and approved by Hunan

338 Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, China (No. [2022]

339 48). The study will be conducted in accordance with the principles of Good Clinical Practice

- 340 and the Declaration of Helsinki. The study has also been registered at the Chinese Clinical Trial
- 341 Registry (ChiCTR2200064756). All participants must give written informed consent which
- 342 should be acquired after a sufficient and detailed explanation of the research situation343 (including confidentiality, risk and benefits, the purpose of the study, etc.).
- 344 **Consent for publication**

345 Not applicable.

- 346 **Competing interests**
- 347 The authors have no competing interests to declare.

349	Ref	ferences				
350	1	van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen C, et al. Vascular cognitive				
351		impairment. Nat Rev Dis Primers. 2018;4:18003. http://doi.org/10.1038/nrdp.2018.3				
352	2	Jia J, Zhou A, Wei C, Jia X, Wang F, Li F, et al. The prevalence of mild cognitive impairment and				
353		its etiological subtypes in elderly Chinese. Alzheimers Dement. 2014;10(4):439-47.				
354		http://doi.org/10.1016/j.jalz.2013.09.008				
355	3	Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, et al. Dementia in China: epidemiology, clinical				
356		management, and research advances. Lancet Neurol. 2020;19(1):81-92.				
357		http://doi.org/10.1016/S1474-4422(19)30290-X				
358	4	Cognitive Impairment Committee of Neurology Branch of Chinese Medical Doctor Association,				
359		Chinese Guidelines for the diagnosis and treatment of vascular cognitive Impairment 2019.				
360		National Medical Journal of China 2019; 99(35): 2737-2744.				
361		http://doi.org/10.3760/cma.j.issn.0376-2491.2019.35.005				
362	5	Litak J. Mazurek M. Kulesza B. Szmygin P. Litak J. Kamieniak P. et al. Cerebral Small Vessel				
363		Disease. Int J Mol Sci. 2020;21(24). http://doi.org/10.3390/ijms21249729				
364	6	Orgeta V, Oazi A, Spector AE, Orrell M. Psychological treatments for depression and anxiety in				
365		dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2014;2014(1):D9125.				
366		http://doi.org/10.1002/14651858.CD009125.pub2				
367	7	Dauphinot V, Potashman M, Levitchi-Benea M, Su R, Rubino I, Krolak-Salmon P. Economic and				
368		caregiver impact of Alzheimer's disease across the disease spectrum: a cohort study. Alzheimers				
369		Res Ther. 2022;14(1):34. http://doi.org/10.1186/s13195-022-00969-x				
370	8	Dichgans M, Leys D. Vascular Cognitive Impairment. Circ Res. 2017;120(3):573-91.				
371		http://doi.org/10.1161/CIRCRESAHA.116.308426				
372	9	Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, et al. Vascular				
373		Cognitive Impairment and Dementia: JACC Scientific Expert Panel. J Am Coll Cardiol.				
374		2019;73(25):3326-44. http://doi.org/10.1016/j.jacc.2019.04.034				
375	10	Xu QQ, Shan CS, Wang Y, Shi YH, Zhang QH, Zheng GQ. Chinese Herbal Medicine for Vascular				
376		Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled				
377		Trials. J Alzheimers Dis. 2018;62(1):429-56. http://doi.org/10.3233/JAD-170856				
378	11	Chang D, Liu J, Bilinski K, Xu L, Steiner GZ, Seto SW, et al. Herbal Medicine for the Treatment				
379		of Vascular Dementia: An Overview of Scientific Evidence. Evid Based Complement Alternat Med.				
380		2016:7293626. http://doi.org/10.1155/2016/7293626				
381	12	Chan ES, Bautista DT, Zhu Y, You Y, Long JT, Li W, et al. Traditional Chinese herbal medicine				
382		for vascular dementia. Cochrane Database Syst Rev. 2018;12(12):D10284.				
383		http://doi.org/10.1002/14651858.CD010284.pub2				
384	13	Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. Efficacy and safety of the compound Chinese				
385		medicine SaiLuoTong in vascular dementia: A randomized clinical trial. Alzheimers Dement (N				
386		Y). 2018;4:108-17. http://doi.org/10.1016/j.trci.2018.02.004				
387	14	Zeng L, Zou Y, Kong L, Wang N, Wang Q, Wang L, et al. Can Chinese Herbal Medicine Adjunctive				
388		Therapy Improve Outcomes of Senile Vascular Dementia? Systematic Review with Meta-				
389		analysis of Clinical Trials. Phytother Res. 2015;29(12):1843-57. http://doi.org/10.1002/ptr.5481				
390	15	Bai X, Zhang M. Traditional Chinese Medicine Intervenes in Vascular Dementia: Traditional				

- 391 Medicine Brings New Expectations. Front Pharmacol. 2021;12:689625.
 392 http://doi.org/10.3389/fphar.2021.689625
- 393 16 Sachdev P, Kalaria R, O'Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular
 394 cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-18.
 395 http://doi.org/10.1097/WAD.0000000000034
- 396 17 Skrobot OA, O'Brien J, Black S, Chen C, DeCarli C, Erkinjuntti T, et al. The Vascular Impairment
 397 of Cognition Classification Consensus Study. Alzheimers Dement. 2017;13(6):624-33.
 398 http://doi.org/10.1016/j.jalz.2016.10.007
- Xue-fei W, Qiang L, Hai-zhen Z, Ying G. Development process of patient-reported outcome draft
 scale of stroke. China Journal of Traditional Chinese Medicine and Pharmacy 2012; 27(02): 292295.
- 402 19 van der Ploeg T, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a
 403 simulation study for predicting dichotomous endpoints. Bmc Med Res Methodol. 2014;14:137.
 404 http://doi.org/10.1186/1471-2288-14-137
- Riley RD, Ensor J, Snell K, Harrell FJ, Martin GP, Reitsma JB, et al. Calculating the sample size
 required for developing a clinical prediction model. BMJ. 2020;368:m441.
 http://doi.org/10.1136/bmj.m441
- 40821McPherson S, Barbosa-Leiker C, Mamey MR, McDonell M, Enders CK, Roll J. A 'missing not at409random' (MNAR) and 'missing at random' (MAR) growth model comparison with a410buprenorphine/naloxoneclinical411http://doi.org/10.1111/add.12714
- 412 22 Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc 1996; 91(434): 473-489. DOI :
- 413 10.2307/2291635
- 414 23 Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English longitudinal study of ageing.
 415 Int J Epidemiol. 2013;42(6):1640-8. http://doi.org/10.1093/ije/dys168
- 416 24 Klaus D, Engstler H, Mahne K, Wolff JK, Simonson J, Wurm S, et al. Cohort Profile: The German
 417 Ageing Survey (DEAS). Int J Epidemiol. 2017;46(4):1105. http://doi.org/10.1093/ije/dyw326
- Zhu Y, Pan D, He L, Rong X, Li H, Li Y, et al. China Registry Study on Cognitive Impairment in
 the Elderly: Protocol of a Prospective Cohort Study. Front Aging Neurosci. 2021;13:797704.
 http://doi.org/10.3389/fnagi.2021.797704
- 421 26 Gliklich R, Dreyer N, and Leavy M. Registries for evaluating patient outcomes: a user's guide.
 422 Third edition (2014). Available at: http://www.effectivehealthcare.ahrq.gov/registries-guide-3.cfm.
- 423 27 Zhang Y. L. Multi center case registration of compound cistanche vizhi capsule in the treatment of 424 vascular dementia world. (2021)Available based on the real at: 425 http://www.chictr.org.cn/showproj.aspx?proj=139594.
- 426 28 Feng L, Kong L, Dong X, Lai X, Zhang D, Ren B, et al. China Stroke Registry for Patients With
 427 Traditional Chinese Medicine (CASES-TCM): Rationale and Design of a Prospective,
 428 Multicenter, Observational Study. Front Pharmacol. 2021;12:743883.
 429 http://doi.org/10.3389/fphar.2021.743883
- 430 29 Ong WY, Wu YJ, Farooqui T, Farooqui AA. Qi Fu Yin-a Ming Dynasty Prescription for the
 431 Treatment of Dementia. Mol Neurobiol. 2018;55(9):7389-400. http://doi.org/10.1007/s12035-018-

432		0908-0				
433	30	Jian-bo H, Guang-ji Z. Origin and innovative development of holism of traditional Chinese				
434		medicine. China Journal of Traditional Chinese Medicine and Pharmacy 2020; 35(01): 35-38. DOI :				
435		CNKI:SUN:BXYY.0.2020-01-006				
436	31	Gaglio B, Henton M, Barbeau A, Evans E, Hickam D, Newhouse R, et al. Methodological standards				
437	for qualitative and mixed methods patient centered outcomes research. BMJ. 20					
438		http://doi.org/10.1136/bmj.m4435				
439	32	2 Ruijin Q, Chen Z, Changming Z, et al. Application of mixed methods research in individuali				
440		therapeutic evaluation of clinical trials of traditional Chinese medicine. Chinese Journal				
441		Evidence-Based Medicine 2020; 20(08): 973-978. DOI: 10.7507/1672-2531.201911079				
442	33	Hongling C, Kaiwen N, Lin Z, et al. The Application of Mixed Methods Research in Real World				
443		Studies. Chinese Journal of Evidence-Based Medicine 2018; 18(11): 1203-1206.				
444		DOI:10.7507/1672-2531.201808035				
445	34	Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an				
446		update. Nat Rev Neurol. 2015;11(3):157-65. http://doi.org/10.1038/nrneurol.2015.10				
447	35	Pasi M, van Uden IW, Tuladhar AM, de Leeuw FE, Pantoni L. White Matter Microstructural				
448		Damage on Diffusion Tensor Imaging in Cerebral Small Vessel Disease: Clinical Consequences.				
449		Stroke. 2016;47(6):1679-84. http://doi.org/10.1161/STROKEAHA.115.012065				
450	36	Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobágyi T, Höglund K, et al. Increased plasma				
451		neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary				
452		tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019;7(1):5.				
453		http://doi.org/10.1186/s40478-018-0649-3				
454	37	Hoyer-Kimura C, Konhilas JP, Mansour HM, Polt R, Doyle KP, Billheimer D, et al. Neurofilament				
455		light: a possible prognostic biomarker for treatment of vascular contributions to cognitive				
456		impairment and dementia. J Neuroinflammation. 2021;18(1):236. http://doi.org/10.1186/s12974-				
457		021-02281-1				
458	38	Walker KA, Gottesman RF, Wu A, Knopman DS, Gross AL, Mosley TJ, et al. Systemic				
459		inflammation during midlife and cognitive change over 20 years: The ARIC Study. Neurology.				
460		2019;92(11):e1256-67. http://doi.org/10.1212/WNL.0000000000007094				
461	39	Erhardt EB, Adair JC, Knoefel JE, Caprihan A, Prestopnik J, Thompson J, et al. Inflammatory				
462		Biomarkers Aid in Diagnosis of Dementia. Front Aging Neurosci. 2021;13:717344.				
463		http://doi.org/10.3389/fnagi.2021.717344				
464						

Table 1 Main variables registered in REVIEW-TCM study

465 466

Field **Property** Variables **Basic information** Identification Gender; Demographic Required card; Age; Ethnicity: Education: Birthplace: Permanent address; Height; Weight; Body Mass Index; Marital status; Occupation; Phone number Disease Required Symptom onset date; Admission date; Course of VCI; Comorbidity Auxiliary examination Required Vital signs; Laboratory tests; ECG Cognition information Required MoCA; HIS; History of treatment Diagnosis Required Diagnostic classification; ZHENG of TCM Required Imaging CT; MRI; Brain lesions Informed consent Required **Treatment information** Traditional Chinese medicine Required TCM therapies; Formulation (Chinese medicine decoctions); patent or Duration; Therapy compliance Western medicine Drugs; Category; Dosage; Duration Required **Outcomes evaluation** TMT-B; Cognition Required MoCA; TMT-A; BNT-2: HVLT; CDT Required IADL Activity of daily living Quality of life EO-5D-5L Required Psychology Required HADS Mental Required NPI ZHENG of TCM Required **SDSVD** Burden of caregiver Zarit Burden Interview Required Safety evaluation Required Adverse events; MACE Health economics Required Occupational status; Full-time care; Assistance needed; Daily medication cost Other information Specific imaging information Optional Infarct or hemorrhage lesions; WMH; Vascular Hippocampal stenosis; atrophy; MD; FA Molecular biology Optional NFL; CRP; LC; VEGF In-depth interview Optional Recording of interview

467

468	CT, Computerized tomography; CRP, C-reactive protein; DTI, Diffusion tensor
469	imaging; ECG, electrocardiogram; FA, Fractional anisotropy; HIS, Hachinski Ischemic
470	Score; LC, Leukocyte count; NFL, Neurofilament light chain; MACE, Major adverse
471	cardiovascular events; MoCA, Montreal Cognitive Assessment; MD, Mean diffusivity;
472	MRI, Magnetic resonance imaging; REVIEW-TCM, Registry for vascular cognitive
473	Impairment treatment with traditional Chinese medicine; TCM, Traditional Chinese
474	medicine; VASCOG, The special symposium of the International Society for Vascular
475	Behavioral and Cognitive Disorders; VEGF, Vascular endothelial growth factor; WMH,
476	White matter hyperintensity.



478

479

Figure 1. The overview of study flowchart of REVIEW-TCM

480 CT, Computerized tomography; CRP, C-reactive protein; DTI, Diffusion tensor 481 imaging; HIS, Hachinski Ischemic Score; LC, Leukocyte count; NFL, Neurofilament 482 light chain; MoCA, Montreal Cognitive Assessment; MRI, Magnetic resonance 483 imaging; REVIEW-TCM, Registry for vascular cognitive Impairment treatment with 484 traditional Chinese medicine; TCM, Traditional Chinese medicine; VASCOG, The 485 special symposium of the International Society for Vascular Behavioral and Cognitive 486 Disorders; VEGF, Vascular endothelial growth factor.

487



Figure 2. Study design of registry for REVIEW-TCM

490 491

489

. . .



Figure1

Different therapies of TCM



Figure2

Table 1 Main variables registered in REVIEW-TCM study

	Field	Property	Variables
	Basic information		
	Demographic	Required	Identification card; Age; Gender; Ethnicity: Education: Birthplace:
			Permanent address: Height: Weight:
			Body Mass Index: Marital status:
			Occupation; Phone number
	Disease	Required	Symptom onset date; Admission date;
			Course of VCI; Comorbidity
medRxiv preprint doi:	http://www.lg/anyoexampnation.		pylitalisigns: Ipaboratory tests; ECG
(which was not cer	Cognition in adeavailable under a CC-BY 4.0 Interr	atimal license to dis	MoCA; HIS; History of treatment
	Diagnosis	Required	Diagnostic classification; ZHENG of TCM
	Imaging	Required	CT; MRI; Brain lesions
	Informed consent	Required	
	Treatment information		
	Traditional Chinese medicine	Required	TCM therapies; Formulation (Chinese
			patent medicine or decoctions);
			Duration; Therapy compliance
	Western medicine	Required	Drugs; Category; Dosage; Duration
	Outcomes evaluation		
	Cognition	Required	MoCA; TMT-A; TMT-B; BNT-2; HVLT; CDT
	Activity of daily living	Required	IADL
	Quality of life	Required	EQ-5D-5L
	Psychology	Required	HADS
	Mental	Required	NPI
	ZHENG of TCM	Required	SDSVD
	Burden of caregiver	Required	Zarit Burden Interview
	Safety evaluation	Required	Adverse events; MACE
	Health economics	Required	Occupational status; Full-time care;
			Assistance needed; Daily medication
			cost
	Other information		
	Specific imaging information	Optional	Infarct or hemorrhage lesions; WMH;
			Vascular stenosis; Hippocampal
			atrophy; MD; FA
	Molecular biology	Optional	NFL; CRP; LC; VEGF
	In-depth interview	Optional	Recording of interview

CT, Computerized tomography; CRP, C-reactive protein; DTI, Diffusion tensor

imaging; ECG, electrocardiogram; FA, Fractional anisotropy; HIS, Hachinski Ischemic Score; LC, Leukocyte count; NFL, Neurofilament light chain; MACE, Major adverse cardiovascular events; MoCA, Montreal Cognitive Assessment; MD, Mean diffusivity; MRI, Magnetic resonance imaging; REVIEW-TCM, Registry for vascular cognitive Impairment treatment with traditional Chinese medicine; TCM, Traditional Chinese medicine; VASCOG, The special symposium of the International Society for Vascular Behavioral and Cognitive Disorders; VEGF, Vascular endothelial growth factor; WMH, White matter hyperintensity.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.24.23290492; this version posted June 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.